<DOC>
	<DOCNO>NCT02063204</DOCNO>
	<brief_summary>A study ass pharmacokinetics , safety tolerability Selumetinib ( AZD6244 , ARRY-142886 ) subject renal impairment healthy subject</brief_summary>
	<brief_title>To Assess Pharmacokinetics , Safety Tolerability Selumetinib Renal Impaired Subjects Healthy Subjects</brief_title>
	<detailed_description>An open label study ass pharmacokinetics , safety tolerability 50 mg single oral dose Selumetinib ( AZD6244 , ARRY-142886 ) subject renal impairment healthy subject</detailed_description>
	<criteria>Inclusion Criteria participant : 1 . Male female ( non childbearing potential ) subject age 18 year suitable vein cannulation repeat venipuncture . 2 . Have weight least 50 kg ( 110 lb ) body mass index ( BMI ) 18 40 kg/m2 , inclusive . Inclusion healthy volunteer : 3 . Must good health determine medical history , physical examination , 12 lead ECG , clinical laboratory evaluation , ophthalmic examination perform administration investigational product . Inclusion renal impaired patient : 4 . Stable renal function Exclusion Criteria participant : 1 . Subjects Japanese non Japanese Asian ethnicity . 2 . Any one parent grandparent ( maternal paternal ) Japanese nonJapanese Asian ( e.g . China , Taiwan , Korea , Philippines , Thailand , Vietnam Malaysia ) . Asian Indians acceptable . 3 . Subjects smoke 10 cigarette equivalent tobacco per day 4 . In opinion investigator , evidence additional severe uncontrolled systemic disease ( eg , currently unstable uncompensated hepatic , cardiovascular , respiratory disease ) laboratory finding , physical examination , hematology , clinical chemistry , urinalysis , vital sign , 12lead ECG make undesirable subject participate study . Exclusion renal impaired patient : 5 . Subjects active renal transplant ( subject previously receive renal transplant currently undergoing dialysis due transplant failure may enrol ) . 6 . Acute coronary syndrome within 6 month prior administration investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase I , healthy , pharmacokinetics , renal impairment</keyword>
</DOC>